Intrinsic value of Editas Medicine, Inc. - EDIT

Previous Close

$23.97

  Intrinsic Value

$1.00

stock screener

  Rating & Target

str. sell

-96%

Previous close

$23.97

 
Intrinsic value

$1.00

 
Up/down potential

-96%

 
Rating

str. sell

We calculate the intrinsic value of EDIT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  51
  79
  118
  172
  242
  333
  447
  587
  755
  954
  1,184
  1,448
  1,745
  2,076
  2,442
  2,840
  3,272
  3,735
  4,230
  4,756
  5,312
  5,897
  6,511
  7,154
  7,826
  8,526
  9,256
  10,014
  10,803
  11,623
Variable operating expenses, $m
  97
  147
  218
  315
  443
  608
  814
  1,068
  1,373
  1,733
  2,147
  2,625
  3,164
  3,765
  4,426
  5,149
  5,931
  6,772
  7,670
  8,623
  9,631
  10,692
  11,805
  12,971
  14,189
  15,458
  16,781
  18,156
  19,587
  21,073
Fixed operating expenses, $m
  111
  114
  116
  119
  122
  124
  127
  130
  133
  135
  138
  142
  145
  148
  151
  154
  158
  161
  165
  168
  172
  176
  180
  184
  188
  192
  196
  200
  205
  209
Total operating expenses, $m
  208
  261
  334
  434
  565
  732
  941
  1,198
  1,506
  1,868
  2,285
  2,767
  3,309
  3,913
  4,577
  5,303
  6,089
  6,933
  7,835
  8,791
  9,803
  10,868
  11,985
  13,155
  14,377
  15,650
  16,977
  18,356
  19,792
  21,282
Operating income, $m
  -157
  -182
  -217
  -262
  -322
  -399
  -494
  -611
  -750
  -915
  -1,101
  -1,319
  -1,563
  -1,836
  -2,136
  -2,463
  -2,818
  -3,198
  -3,604
  -4,035
  -4,491
  -4,970
  -5,474
  -6,000
  -6,550
  -7,124
  -7,721
  -8,342
  -8,988
  -9,659
EBITDA, $m
  -148
  -170
  -200
  -241
  -294
  -361
  -445
  -547
  -669
  -814
  -980
  -1,171
  -1,385
  -1,624
  -1,887
  -2,174
  -2,484
  -2,817
  -3,172
  -3,550
  -3,949
  -4,369
  -4,809
  -5,270
  -5,752
  -6,254
  -6,776
  -7,320
  -7,886
  -8,473
Interest expense (income), $m
  0
  2
  -1
  2
  8
  15
  24
  36
  51
  70
  92
  118
  149
  184
  224
  268
  316
  369
  426
  488
  554
  623
  697
  775
  856
  942
  1,031
  1,124
  1,221
  1,322
  1,426
Earnings before tax, $m
  -159
  -181
  -219
  -270
  -337
  -423
  -530
  -662
  -820
  -1,007
  -1,220
  -1,468
  -1,748
  -2,060
  -2,404
  -2,779
  -3,186
  -3,624
  -4,092
  -4,589
  -5,114
  -5,668
  -6,249
  -6,857
  -7,492
  -8,155
  -8,845
  -9,563
  -10,310
  -11,086
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -159
  -181
  -219
  -270
  -337
  -423
  -530
  -662
  -820
  -1,007
  -1,220
  -1,468
  -1,748
  -2,060
  -2,404
  -2,779
  -3,186
  -3,624
  -4,092
  -4,589
  -5,114
  -5,668
  -6,249
  -6,857
  -7,492
  -8,155
  -8,845
  -9,563
  -10,310
  -11,086

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  140
  216
  323
  469
  662
  910
  1,221
  1,603
  2,063
  2,606
  3,236
  3,956
  4,768
  5,673
  6,671
  7,760
  8,939
  10,205
  11,558
  12,995
  14,513
  16,113
  17,791
  19,548
  21,383
  23,296
  25,289
  27,362
  29,518
  31,758
Adjusted assets (=assets-cash), $m
  140
  216
  323
  469
  662
  910
  1,221
  1,603
  2,063
  2,606
  3,236
  3,956
  4,768
  5,673
  6,671
  7,760
  8,939
  10,205
  11,558
  12,995
  14,513
  16,113
  17,791
  19,548
  21,383
  23,296
  25,289
  27,362
  29,518
  31,758
Revenue / Adjusted assets
  0.364
  0.366
  0.365
  0.367
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
Average production assets, $m
  64
  98
  147
  214
  302
  414
  556
  731
  940
  1,187
  1,474
  1,803
  2,173
  2,585
  3,040
  3,536
  4,073
  4,650
  5,267
  5,921
  6,613
  7,342
  8,107
  8,907
  9,743
  10,615
  11,523
  12,468
  13,450
  14,471
Working capital, $m
  -48
  -74
  -111
  -161
  -228
  -313
  -420
  -552
  -710
  -896
  -1,113
  -1,361
  -1,640
  -1,952
  -2,295
  -2,670
  -3,075
  -3,511
  -3,976
  -4,471
  -4,993
  -5,543
  -6,121
  -6,725
  -7,356
  -8,015
  -8,700
  -9,414
  -10,155
  -10,926
Total debt, $m
  -26
  43
  139
  270
  444
  667
  947
  1,291
  1,705
  2,193
  2,760
  3,409
  4,140
  4,954
  5,852
  6,832
  7,893
  9,033
  10,251
  11,544
  12,910
  14,350
  15,860
  17,441
  19,093
  20,815
  22,608
  24,474
  26,414
  28,431
Total liabilities, $m
  126
  195
  291
  422
  595
  819
  1,099
  1,443
  1,857
  2,345
  2,912
  3,560
  4,291
  5,106
  6,004
  6,984
  8,045
  9,185
  10,402
  11,695
  13,062
  14,501
  16,012
  17,593
  19,244
  20,966
  22,760
  24,626
  26,566
  28,582
Total equity, $m
  14
  22
  32
  47
  66
  91
  122
  160
  206
  261
  324
  396
  477
  567
  667
  776
  894
  1,021
  1,156
  1,299
  1,451
  1,611
  1,779
  1,955
  2,138
  2,330
  2,529
  2,736
  2,952
  3,176
Total liabilities and equity, $m
  140
  217
  323
  469
  661
  910
  1,221
  1,603
  2,063
  2,606
  3,236
  3,956
  4,768
  5,673
  6,671
  7,760
  8,939
  10,206
  11,558
  12,994
  14,513
  16,112
  17,791
  19,548
  21,382
  23,296
  25,289
  27,362
  29,518
  31,758
Debt-to-equity ratio
  -1.850
  1.980
  4.300
  5.760
  6.710
  7.330
  7.760
  8.050
  8.260
  8.420
  8.530
  8.620
  8.680
  8.730
  8.770
  8.800
  8.830
  8.850
  8.870
  8.880
  8.900
  8.910
  8.910
  8.920
  8.930
  8.930
  8.940
  8.940
  8.950
  8.950
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -159
  -181
  -219
  -270
  -337
  -423
  -530
  -662
  -820
  -1,007
  -1,220
  -1,468
  -1,748
  -2,060
  -2,404
  -2,779
  -3,186
  -3,624
  -4,092
  -4,589
  -5,114
  -5,668
  -6,249
  -6,857
  -7,492
  -8,155
  -8,845
  -9,563
  -10,310
  -11,086
Depreciation, amort., depletion, $m
  9
  12
  16
  22
  29
  38
  50
  64
  81
  101
  121
  148
  178
  212
  249
  290
  334
  381
  432
  485
  542
  602
  664
  730
  799
  870
  945
  1,022
  1,102
  1,186
Funds from operations, $m
  -150
  -169
  -203
  -248
  -308
  -385
  -481
  -598
  -739
  -906
  -1,099
  -1,320
  -1,569
  -1,848
  -2,154
  -2,490
  -2,853
  -3,243
  -3,660
  -4,103
  -4,572
  -5,066
  -5,584
  -6,127
  -6,694
  -7,285
  -7,900
  -8,541
  -9,207
  -9,899
Change in working capital, $m
  -18
  -26
  -37
  -50
  -66
  -85
  -107
  -132
  -158
  -187
  -217
  -248
  -279
  -311
  -343
  -375
  -406
  -436
  -465
  -494
  -522
  -550
  -577
  -604
  -631
  -658
  -686
  -713
  -742
  -771
Cash from operations, $m
  -132
  -142
  -166
  -198
  -242
  -300
  -374
  -467
  -581
  -719
  -882
  -1,072
  -1,290
  -1,536
  -1,811
  -2,115
  -2,447
  -2,807
  -3,195
  -3,609
  -4,050
  -4,516
  -5,007
  -5,522
  -6,062
  -6,626
  -7,215
  -7,828
  -8,466
  -9,129
Maintenance CAPEX, $m
  -3
  -5
  -8
  -12
  -18
  -25
  -34
  -46
  -60
  -77
  -97
  -121
  -148
  -178
  -212
  -249
  -290
  -334
  -381
  -432
  -485
  -542
  -602
  -664
  -730
  -799
  -870
  -945
  -1,022
  -1,102
New CAPEX, $m
  -24
  -35
  -49
  -66
  -88
  -113
  -142
  -174
  -209
  -247
  -287
  -328
  -370
  -412
  -455
  -496
  -537
  -577
  -616
  -655
  -692
  -729
  -765
  -801
  -836
  -872
  -908
  -945
  -982
  -1,021
Cash from investing activities, $m
  -27
  -40
  -57
  -78
  -106
  -138
  -176
  -220
  -269
  -324
  -384
  -449
  -518
  -590
  -667
  -745
  -827
  -911
  -997
  -1,087
  -1,177
  -1,271
  -1,367
  -1,465
  -1,566
  -1,671
  -1,778
  -1,890
  -2,004
  -2,123
Free cash flow, $m
  -159
  -182
  -223
  -277
  -347
  -437
  -549
  -686
  -850
  -1,043
  -1,267
  -1,521
  -1,808
  -2,127
  -2,478
  -2,860
  -3,274
  -3,718
  -4,192
  -4,695
  -5,227
  -5,786
  -6,373
  -6,987
  -7,629
  -8,297
  -8,993
  -9,717
  -10,470
  -11,252
Issuance/(repayment) of debt, $m
  -58
  69
  96
  131
  173
  223
  280
  344
  414
  488
  567
  648
  731
  815
  898
  980
  1,061
  1,140
  1,217
  1,293
  1,367
  1,439
  1,510
  1,581
  1,651
  1,722
  1,793
  1,866
  1,940
  2,017
Issuance/(repurchase) of shares, $m
  270
  188
  230
  285
  356
  448
  561
  700
  866
  1,061
  1,283
  1,540
  1,829
  2,150
  2,503
  2,888
  3,304
  3,751
  4,227
  4,732
  5,266
  5,827
  6,416
  7,032
  7,676
  8,346
  9,044
  9,770
  10,525
  11,310
Cash from financing (excl. dividends), $m  
  212
  257
  326
  416
  529
  671
  841
  1,044
  1,280
  1,549
  1,850
  2,188
  2,560
  2,965
  3,401
  3,868
  4,365
  4,891
  5,444
  6,025
  6,633
  7,266
  7,926
  8,613
  9,327
  10,068
  10,837
  11,636
  12,465
  13,327
Total cash flow (excl. dividends), $m
  53
  75
  103
  139
  182
  234
  292
  358
  430
  506
  583
  667
  752
  838
  923
  1,008
  1,091
  1,173
  1,252
  1,330
  1,406
  1,480
  1,554
  1,626
  1,699
  1,771
  1,845
  1,919
  1,996
  2,074
Retained Cash Flow (-), $m
  -270
  -188
  -230
  -285
  -356
  -448
  -561
  -700
  -866
  -1,061
  -1,283
  -1,540
  -1,829
  -2,150
  -2,503
  -2,888
  -3,304
  -3,751
  -4,227
  -4,732
  -5,266
  -5,827
  -6,416
  -7,032
  -7,676
  -8,346
  -9,044
  -9,770
  -10,525
  -11,310
Prev. year cash balance distribution, $m
  333
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  116
  -114
  -126
  -146
  -174
  -214
  -269
  -342
  -437
  -555
  -700
  -873
  -1,077
  -1,312
  -1,580
  -1,880
  -2,213
  -2,578
  -2,975
  -3,402
  -3,860
  -4,347
  -4,863
  -5,406
  -5,977
  -6,575
  -7,200
  -7,851
  -8,530
  -9,236
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  111
  -104
  -110
  -120
  -135
  -155
  -182
  -214
  -251
  -291
  -332
  -373
  -409
  -441
  -464
  -478
  -482
  -475
  -458
  -432
  -399
  -361
  -319
  -275
  -233
  -192
  -155
  -121
  -93
  -70
Current shareholders' claim on cash, %
  50.0
  13.5
  4.3
  1.6
  0.6
  0.3
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

FINANCIAL RATIOS  of  Editas Medicine, Inc. (EDIT)

Valuation Ratios
P/E Ratio -8.9
Price to Sales 143.1
Price to Book 6.4
Price to Tangible Book
Price to Cash Flow -17.2
Price to Free Cash Flow -16.2
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 200%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 19
Current Ratio 0
LT Debt to Equity 25.9%
Total Debt to Equity 33.3%
Interest Coverage 0
Management Effectiveness
Return On Assets -51.3%
Ret/ On Assets - 3 Yr. Avg. -114%
Return On Total Capital -65.3%
Ret/ On T. Cap. - 3 Yr. Avg. -248.3%
Return On Equity -77%
Return On Equity - 3 Yr. Avg. -252.2%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -1600%
EBITDA Margin - 3 Yr. Avg. -1750%
Operating Margin -1616.7%
Oper. Margin - 3 Yr. Avg. -1122.2%
Pre-Tax Margin -1616.7%
Pre-Tax Margin - 3 Yr. Avg. -1755.6%
Net Profit Margin -1616.7%
Net Profit Margin - 3 Yr. Avg. -1755.6%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

EDIT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EDIT stock intrinsic value calculation we used $32 million for the last fiscal year's total revenue generated by Editas Medicine, Inc.. The default revenue input number comes from 0001 income statement of Editas Medicine, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EDIT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EDIT is calculated based on our internal credit rating of Editas Medicine, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Editas Medicine, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EDIT stock the variable cost ratio is equal to 193.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $109 million in the base year in the intrinsic value calculation for EDIT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Editas Medicine, Inc..

Corporate tax rate of 27% is the nominal tax rate for Editas Medicine, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EDIT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EDIT are equal to 124.5%.

Life of production assets of 12.2 years is the average useful life of capital assets used in Editas Medicine, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EDIT is equal to -94%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $236.162 million for Editas Medicine, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 48.991 million for Editas Medicine, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Editas Medicine, Inc. at the current share price and the inputted number of shares is $1.2 billion.

RELATED COMPANIES Price Int.Val. Rating
SGMO Sangamo Therap 9.80 2.23  str.sell
BLUE bluebird bio, 156.17 8.46  str.sell
NTLA Intellia Thera 16.71 1.54  str.sell
ABEO Abeona Therape 8.09 0.70  str.sell
CLLS Cellectis S.A. 19.75 2.76  str.sell
AGTC Applied Geneti 4.25 6.63  str.buy
RGNX REGENXBIO Inc. 58.36 3.50  str.sell

CONTACT US       ASSET ALLOCATION

About X-FIN       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2019. All rigths reserved.